Texas Roadhouse, Inc.
$13.20B- Market cap
- $12.44B
- Debt
- +$885.30M
- Cash
- −$134.71M
Capital structure 93% equity / 7% debt · EV / Revenue 2.24x · EV / EBITDA 27.03x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: TXRH stock price at discount vs CTXR $189.59 current versus $16.08K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Implied fair value · at TXRH's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: TXRH FY 2025 (ended Dec 30, 2025) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 93% equity / 7% debt · EV / Revenue 2.24x · EV / EBITDA 27.03x
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
TXRH carries the larger enterprise value at $13.20B against -$31.66M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 27.03x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Texas Roadhouse, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.61x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
1.54x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$134.71M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BRINKER INTERNATIONAL, INC
TXRH vs EAT
Bloomin' Brands, Inc.
TXRH vs BLMN
DARDEN RESTAURANTS INC
TXRH vs DRI
BJs RESTAURANTS INC
TXRH vs BJRI
Zomedica Corp.
TXRH vs ZOM
Aquestive Therapeutics, Inc.
TXRH vs AQST
ACADIA PHARMACEUTICALS INC
TXRH vs ACAD
AMGEN INC
TXRH vs AMGN
GILEAD SCIENCES, INC.
TXRH vs GILD
AbbVie Inc.
TXRH vs ABBV
$885.30M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.